IL17A and atherosclerosis: The treatment of DPVD by SMYAD mainly involves pathways such as Lipid and atherosclerosis, AGE-RAGE signaling pathway, Interleukin IL-17 signaling pathway, TNF signaling pathway, etc. The docking structure of the active ingredients and the core targets in the study is stable and responds well.